Thoracic
DeviceImplant of a Relay stent graft system
NCT Number: NCT04246463
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Imeldaziekenhuis, Bonheiden, Belgium
Post Market registry collecting real world, post-approval safety, performance, patient reported outcomes and health economic data on patients treated with Terumo Aortic endovascular stent-grafts in standard clinical practice.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
o Emergent cases (typically younger patients with traumatic injuries) are not excluded if there is IRB/EC agreement to allow consent after intervention (i.e. consent to study participation, not to treatment) or use of a Legally Authorized Representative (LAR).
Exclusion criteria
Patient is unable or unwilling to comply with the study follow-up regime. Patient is contraindicated per the IFU, or has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving treatment as well as the procedures and evaluations pre and post procedure.
Implant of a Relay stent graft system
Implant with an Anaconda or Treo Stent graft system
Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
Implant with an Anaconda Iliac leg only
Time frame: 30 days post implant
Defined as any death occurring within 30 days of implant, due to rupture or following any procedure intended to treat the target lesion
Time frame: Day 0
defined as:
Successful delivery of the device through the vasculature (i.e. ability to deliver the implant to the intended location without the need for unanticipated corrective intervention related to delivery).
Deployment of the endovascular stent-graft in the planned location with coverage of the target lesion (or entry tear in the case of dissection);Absence of unplanned coverage or aortic branch vessels; Patency of the endovascular stent-graft, absence of device deformations (e.g. kinks, stent eversion, maldeployment, misaligned deployment) requiring unplanned placement of an additional device within the endovascular stentgraft, and;Successful withdrawal (i.e. successful withdrawal of the delivery system, without the need for unanticipated corrective intervention related to withdrawal). Absence of Type Ia, Type Ib, Type IIIa and IIIb endoleak that extends beyond 30 days by confirmatory imaging (CTA, magnetic resonance angiography [MRA], or duplex ultrasound).
Time frame: 1 year
defined as the absence of: Target lesion related mortality Type Ia, Ib, IIIa and IIIb endoleak Graft infection Stent patency <50% Target lesion aortic rupture Conversion to open repair Arrest of the original pathological process (e.g., total aortic diameter expansion >5 mm in the aorta that has a study endograft, embolization from penetrating ulcer, extension of dissection, false lumen perfusion) or a new aortic pathology as a result of the intervention (e.g., pseudoaneurysm, dissection, intramural hematoma, unintentional adverse dissection septum rupture, stent-graft induced aortic wall injury, new aortobronchial/tracheal or aortoenteric fistula formation)
Time frame: 1 year
All-cause mortality Safety (MAEs, all related adverse events) Target lesion reintervention, all secondary interventions Device performance based on imaging assessments of all morphological variables (aortic remodeling, all endoleaks, any loss of patency, stent-graft migration, device integrity, etc.)
Time frame: 1 Year
Time frame: From Procedure to 1 Year
The following health economic will also be summarized:
Total procedure time (mins) Fluoroscopy time (mins) Blood loss (ml) Blood transfusion required (ml) Time in ICU (hours/mins) Time to hospital discharge (days) Total Procedure time (mins) Total anesthesia time (hours) Total Procedure to discharge time (hours/days)
Time frame: Day 0
The following health economic will also be summarized:
Arterial access route and type (Percutaneous or Cut down)
Time frame: Day 0
The following health economic will also be summarized:
Volume of contrast media used Volume of Blood loss Volume of Blood transfusion required
Time frame: Day 0
The following health economic will also be summarized:
Type of Image fusion technology used Type of Magnet system used
Contact information is provided by the study sponsor or research team.
Michelle Durnan
CONTACT
Sammy Jassal
CONTACT
Vascutek Ltd.
Industry
A Global Post Market Evaluation of Terumo Aortic Endovascular Grafts
Acronym: TiGER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05143138
Abdominal Aortic Aneurysm, Aneurysm
Aarhus, Denmark
View Trial DetailsNCT05378347
Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Loma Linda, California, United States
View Trial DetailsNCT06244732
Abdominal Aortic Aneurysm, Aneurysm
San Donato Milanese, Milan, Italy
View Trial DetailsNCT05665101
Abdominal Aortic Aneurysm, Aneurysm
Munich, Bavaria, Germany
View Trial Details